ForteBio is now part of the Sartorius group. Click here for more
Chunyan Wang, et al., March 2020 Read More
Chunyun Sun, et al., February 2020 Read More
Xiaolong Tian, et al., 9(1): 382–385, Emerg Microbes Infect. 2020 The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including…
Daniel Wrapp, et al., Vol. 367, Issue 6483, pp. 1260-1263 , Science 13 Mar 2020 Read More
ForteBio has developed a quick, high-throughput, and robust AAV2 capsid quantification method, capable of virus titer determination in samples along the purification process.
In this application note, we describe the development of an assay for quantifying AAV2 virus particles in gene therapy.
This document describes the optimization of upstream bioprocessing into higher production of target biologics with the Octet RED384 and HTX systems.